Meet the Two 17-year-olds Who Skipped 60 Days of School to Build a $12.5M NeuroTech Startup | Sai Mattapalli and Rohan Kalahasty

In the dynamic realm of entrepreneurship, where seasoned professionals often take center stage, the story of Sai Mattapalli and Rohan Kalahasty — both 17-year-old high school seniors — emerges as a beacon of inspiration.

These two young minds are not only defying the conventions of their age, but also rewriting the narrative of what is achievable in the business landscape. As the founders and CEOs of, they have embarked on a remarkable journey, crafting a $12.5 million NeuroTech startup while still navigating the hallways of their high school. stands at the forefront of innovation, harnessing state-of-the-art AI systems to enable 30-second brain health evaluations from the comfort of one’s home. What makes this narrative truly compelling is not just the groundbreaking technology, but the unconventional path these entrepreneurs have taken. Mattapalli and Kalahasty embarked on this entrepreneurial adventure during the third quarter of their sophomore year, navigating the intricate balance between homework assignments and investor meetings.

The genesis of

In the corridors of high school, where textbooks and conventional aspirations define the norm, Mattapalli and Kalahasty dared to venture beyond. These two sophomores, fueled by a shared passion for technology and a vision for transforming healthcare, laid the foundation for what would evolve into

It was during the unassuming third quarter of their sophomore year that came to fruition. Driven by a curiosity for artificial intelligence, Mattapalli and Kalahasty began weaving together the threads of their NeuroTech startup. While their peers delved into academic subjects, these young minds were navigating the complexities of building a venture that would reshape the intersection of technology and healthcare.

Unveiling A revolution in brain health evaluation

At its core, is not merely a startup — it’s a paradigm shift in the way we approach brain health evaluations. The company aims to harness the power of state-of-the-art AI systems to provide 30-second brain health evaluations from the comfort of one’s home.

In a recent article by News Medical, it was noted that AI-based systems have significantly aided neuroscientists in testing hypotheses and analyzing neuroimaging data. “By harnessing the capabilities of AI, we gain the ability to navigate the intricate landscape of brain diseases with a finesse that surpasses the reach of traditional diagnostic methods,” Mattapalli concurs.

As a NeuroTech startup, goes beyond the conventional boundaries of health technology, aiming to democratize access to crucial brain health insights. The company’s founders envision a future where individuals can effortlessly assess and prioritize their mental well-being, transcending the barriers of traditional healthcare systems.

“AI can not only provide an early detection diagnosis, but could also predict a brain disorder based on robust data,” Kalahasty affirms.

60 days missed: A junior year deviation

In a bold deviation from the conventional high school journey, Mattapalli and Kalahasty made a strategic decision during their junior year: to miss a total of 60 school days. This wasn’t a manifestation of a rebellious streak, but rather a calculated sacrifice in the name of

The two young entrepreneurs redirected their focus to jet off and engage in critical investor meetings or to huddle together for last-minute product iterations. The significance of this deviation goes beyond mere numbers to symbolize a profound commitment to the growth and development of It paints a picture of teenagers willingly choosing the uncertainties of entrepreneurship over the predictability of traditional education — a testament to the priority they assigned to their startup amidst the pivotal years of their academic journey.

The 60 days missed during their junior year stand as a bold declaration that, for Mattapalli and Kalahasty, the pursuit of their entrepreneurial vision eclipsed the confines of a conventional high school calendar.

The team behind

While Mattapalli and Kalahasty may be the faces of, the heart of their NeuroTech startup beats with the collective efforts of a dedicated team, largely composed of their fellow high school peers. Collaborating with other students from their high school, Mattapalli and Kalahasty built a team that defies the traditional hierarchy of corporate structures, bringing together diverse skill sets, with each member contributing a unique perspective to the intricate tapestry of’s development.

The collaboration was not without its challenges, however, as the team navigated the delicate balance of being both classmates and co-workers, but the fusion of youthful energy and untapped potential proved to be a potent recipe for innovation. Together, they faced the trials of startup life, contributing to the ideation, development, and evolution of

Inspiring entrepreneurship at any age

Beyond the groundbreaking technology and the compelling journey of, Mattapalli and Kalahasty are driven by a larger mission: to dispel the myth that age is a limiting factor in the realm of entrepreneurship. As high school seniors leading a multi-million-dollar startup, they stand as living proof that ambition knows no age boundaries.’s founders aim to inspire and encourage young minds to pursue their entrepreneurial aspirations fearlessly. They understand well how the audacity to dream and the willingness to take risks can lead to extraordinary outcomes, regardless of one’s age or background. Through their story, Mattapalli and Kalahasty hope to instill confidence in the next generation of innovators, urging them to embrace their ideas and turn them into reality.

The lessons drawn from’s journey extend beyond the confines of technology and business strategy, as both founders actively challenge the notion that success is reserved for those with more years under their belt. In exploring the narrative of, we not only witness the birth of a revolutionary startup, but also a call to arms for aspiring entrepreneurs of all ages — a call to defy expectations, break barriers, and embark on the path of innovation.

Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Experts Views and Opinions

The creation of CAR T cell therapy begins with collection of the patient’s blood and separation of the lymphocytes. These include T cells, B cells, and innate lymphoid cells, all of which are separated through apheresis (leukapheresis). It is this separation process which, if optimized, has the potential to revolutionize immunotherapy treatments for cancer patients.
The latest results from a clinical trial presented today at the VEITHsymposium in New York City demonstrate how new living blood vessels created through restorative medical devices have become reality and can open unthinkable treatment avenues for patients. Xeltis is developing cardiovascular devices, namely artificial vessels and valves, that gradually create living and long-lasting vessels made of patients’ own, new healthy tissue.
Within two years, the U.S. will have a shortage of 98,700 medical and lab technologists and more than 80% of health systems are currently reporting shortages in their radiology departments. More than half of the radiologists in the U.S. are 55 and older, and the flow of residents to fill the gap isn’t nearly big enough. The staffing shortage is even more acute among radiation technologists and in the U.K., 97% of radiology departments cannot meet diagnostic reporting requirements.
Dr. Litwin advises, "Approximately 60 study sites worldwide are participating in RESPONDER-HF, a randomized clinical trial of the Corvia Atrial Shunt." What to know more about this life-saving device? Read what this expert has to say.
Fisher writes, "As a result of this shift in thinking, thankfully more and more people have begun seeking behavioral healthcare. Those seeking care are often in crisis requiring providers to not only be fast, but empathetic. One unexpected source powering these to crucial connections? Marketing attribution tools." Read on to learn more.

By using this website you agree to accept Medical Device News Magazine Privacy Policy